Search

Your search keyword '"Sliutz G"' showing total 190 results
Start Over Author "Sliutz G"
190 results on '"Sliutz G"'

7. Prostate specific antigen (PSA) in breast and ovarian cancer

Author

Kucera E, Kainz C, Tempfer C, Robert Zeillinger, Koelbl H, and Sliutz G

Subjects
Immunoassay, Male, Ovarian Neoplasms, Cytosol, Luminescent Measurements, Humans, Prostatic Neoplasms, Breast Neoplasms, Female, Adenocarcinoma, Prostate-Specific Antigen, Prognosis, Neoplasm Staging
Abstract

Prostatic specific antigen (PSA) is commonly used for the diagnosis and monitoring of prostatic adenocarcinoma, and has recently been detected in breast cancer and it is also thought to be produced by ovarian cancer. To examine the prognostic value of PSA tumor expression, we investigated the tumor cytosols of 26 patients with breast cancer and of 16 women with ovarian cancer. We used a chemiluminescence immunoassay for the quantitative determination of PSA (detection limit 0.003 ng/ml). The median PSA level in breast cancer patients was 0.31 ng/mg (minimum 0.003, maximum 4.4). PSA expression was significantly lower in poorly differentiated breast cancers compared to moderately and highly differentiated tumors. Advanced lymph node metastases were also correlated with lower PSA expression. We found no correlation with relapse free or overall survival. Median PSA level in our ovarian cancer patient collective was 0.014 ng/mg (minimum 0.003, maximum 0.046). We found a significant correlation between PSA expression and the estrogen receptor content of the tumor. PSA expression showed no correlation with histological grading, tumor size or other tumor characteristics in ovarian cancer. There was no correlation with relapse free or overall survival in ovarian cancer patients. Our study demonstrates that PSA is expressed in ovarian malignancies but at a lower level compared to breast cancer tissue. PSA was not able to identify a subset of patients with good prognosis in breast and in ovarian cancer patients.

Published
1998

9. Serum evaluation of basic FGF in breast cancer patients

Author

Sliutz, G., Tempfer, C., Andreas Obermair, Dadak Ch., and Kainz Ch.

Subjects
Adult, Aged, 80 and over, Breast Neoplasms, Middle Aged, Sensitivity and Specificity, Survival Analysis, Disease-Free Survival, Neoplasm Proteins, Austria, Lymphatic Metastasis, Biomarkers, Tumor, Humans, Female, Fibroblast Growth Factor 2, Life Tables, Neoplasm Recurrence, Local, Aged, Follow-Up Studies
Abstract

Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen found in a variety of normal and tumour tissues and is of prognostic relevance in human malignancies such as renal cell carcinoma and leukaemia. This study presents the data of 104 serum samples of 20 patients suffering from breast cancer. Mean serum levels of bFGF in these patients were 13.9 +/- 17. 1 (min 0, max 56.4) pg/ml and 2.4 +/- 5.9 (min 0, max 24.7) pg/ml, respectively (p = 0.01). Basic FGF reached a sensitivity of 61% at a specificity of 87% when applying a cut-off level of 5 pg/ml. A continuous increase of bFGF serum levels before the clinical detection of relapse (lead time) was seen in 3 out of 8 cases with a mean lead time of 4 months. Preoperative serum levels were not of prognostic value and showed no correlation with axillary lymph node metastasis. These preliminary results indicate that, in breast cancer patients, soluble bFGF may be useful in early detection of primary tumours, recurrences and monitoring of therapy.

Published
1995

12. [Epidermal growth factor receptor in human breast cancer: correlation with steroid receptors, tumor stage, grading and menopausal status]

Author

Speiser P, Sliutz G, Robert Zeillinger, Czerwenka K, Jakesz R, Knogler W, Kury F, Reiner A, Sevelda P, and Schneeberger C

Subjects
ErbB Receptors, Neoplasms, Hormone-Dependent, Receptors, Estrogen, Lymphatic Metastasis, Humans, Breast Neoplasms, Female, Breast, Lymph Nodes, Menopause, Prognosis, Receptors, Progesterone, Neoplasm Staging
Abstract

In this study, correlations between the epidermal growth factor receptor (EGF-R), steroid receptors, and other prognostic parameters (grading, pTNM-status, menopausal status) were analysed in 326 primary breast carcinomas. 19% of the tumour samples were EGF-R positive, 63% were estrogen receptor (ER) and 54% progesteron receptor (PR) positive. Both steroid receptors were positive in 46% of all samples. We found a highly significant inverse correlation between EGF-R and steroid receptors. 88% of the ER positive tumours were EGF-R negative (p less than 5 x 10(-5)), 90% of the PR positive tumours were EGF-R negative (p less than 5 x 10(-5)) and 91% of the ER plus PR positive tumours were ERF-R negative (p less than 1 x 10(-6)). Grading was available in 170 cases. Six (4%) of the carcinomas were highly differentiated (G1), 82 (48%) were classified as G2, and another 82 (48%) were poorly differentiated (G3). A combination of negative ER and positive EGF-R was found more often in the population of G3 tumours. EGF-R was also positively correlated to tumour size. With regard to receptor status, we did not find a correlation with lymph node involvement. The ER correlated negatively (p less than 1.3 x 10(-5) and the EGF-R positively (p less than 0.042) with menopausal status. Thus, EGF-R overexpression seems to be a marker of morphological and functional dedifferentiation which is associated with a loss of steroid dependency and an increase of an autostimulatory-paracrine growth control. These changes seem to be related to poor prognosis.

Published
1992

16. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation

Author

Fd, Kury, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Robert Zeillinger, and Spona J

Subjects
Ovarian Neoplasms, Receptor, ErbB-2, Breast Neoplasms, DNA, DNA, Neoplasm, Centrifugation, Isopycnic, Proto-Oncogene Mas, Cell Line, Gene Expression Regulation, Neoplastic, Blotting, Southern, Proto-Oncogene Proteins, Humans, RNA, Female, RNA, Neoplasm, Laryngeal Neoplasms, Nucleic Acid Amplification Techniques
Abstract

A rapid, simple and non-toxic procedure for the simultaneous isolation of DNA and RNA from tumor tissue and cells grown in vitro is described. Guanidinium isothiocyanate was used for homogenization of tumor tissue and for cell lysis. Separation of proteins, DNA and RNA was carried out by isopycnic centrifugation in cesium trifluoroacetate. DNA was further purified by salting out residual protein. Nucleic acids prepared by this method from 47 primary human carcinomas and 17 human cell lines were analysed for amplification and expression of the HER-2/neu proto-oncogene. 2- to 10-fold amplification of HER-2/neu was noted in 7/22 mammary carcinomas (32%) and in 4/14 ovarian carcinomas (28%). No amplification of the proto-oncogene was found in 4 laryngeal carcinomas, 1 pharyngeal carcinoma, 2 retrolingual carcinomas, 3 gastric carcinomas and 1 kidney carcinoma. HER-2/neu overexpression was observed in 6/22 of mammary carcinomas (27%) and 7/14 of ovarian carcinomas (50%). No overexpression was found in all other carcinomas studied. Concordance between amplification and overexpression was noted in 3 mammary and 4 ovarian carcinomas, respectively. 3 mammary and 3 ovarian carcinomas showed overexpression without amplification. 5 human mammary carcinoma cell lines showed both amplification and overexpression of HER-2/neu. In two mammary carcinoma cell lines (MDA MB-453 and ZR 75-1) overexpression was noted without amplification of the proto-oncogene. These data combine to suggest that mechanisms other than gene amplification may also lead to overexpression of the HER-2/neu protooncogene in cancer cells.

Published
1990

27. Serum in cervical cancer patients

Author

Sliutz, G., primary, Tempfer, C., additional, Hanzal, E., additional, Reinthaller, A., additional, Koelbl, H., additional, Zeillinger, R., additional, and Kainz, Ch., additional

Published
1997
Full Text
View/download PDF

43. Gesteigerte Zinkausscheidung bei Patientinnen mit Ovarialtumoren

Author

Marth, C., primary, Artner-Dworzak, E., additional, Graf, A., additional, Kapshammer, E., additional, Meusburger, H., additional, Denison, U., additional, Euith, L.C., additional, Sliutz, G., additional, Fuchs, D., additional, Stummvoll, W., additional, Concin, H., additional, Medl, M., additional, Windbichler, G., additional, Leodolter, S., additional, Staudach, A., additional, Salzer, H., additional, Wachter, H., additional, and Dapunt, O., additional

Published
1994
Full Text
View/download PDF

48. Epidermaler Wachstumsfaktor-Rezeptor im humanen Mammakarzinom: Korrelation mit Steroidrezeptoren, Tumorstadium, Grading und Menopausestatus

Author

Speiser, P., primary, Sliutz, G., additional, Zeillinger, R., additional, Czerwenka, K., additional, Jakesz, R., additional, Knogler, W., additional, Kury, F., additional, Reiner, A., additional, Sevelda, P., additional, Schneeberger, Ch., additional, Spona, J., additional, Zielinski, Ch., additional, and Kubista, E., additional

Published
1992
Full Text
View/download PDF

49. Expression of cathepsin D in head and neck cancer

Author

Zeillinger, R., primary, Swoboda, H., additional, Machacek, E., additional, Nekahm, D., additional, Sliutz, G., additional, Knogler, W., additional, Speiser, P., additional, Swoboda, E., additional, and Kubista, E., additional

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results